UK markets open in 3 hours 53 minutes
NIKKEI 225
26,238.40 -672.80 (-2.50%) HANG SENG
20,079.66 -564.62 (-2.73%) CRUDE OIL
110.46 +0.87 (+0.79%) GOLD FUTURES
1,813.90 -2.00 (-0.11%) DOW
31,490.07 -1,164.52 (-3.57%) BTC-GBP
23,558.20 -929.21 (-3.79%)
Silence Therapeutics plc (SLNCF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
At close: 10:21AM EDT
| Previous close | 6.75 |
| Open | 6.75 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 6.75 - 6.75 |
| 52-week range | 5.00 - 26.69 |
| Volume | |
| Avg. volume | 395 |
| Market cap | 606.091M |
| Beta (5Y monthly) | 1.16 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Silence Therapeutics (LON:SLN) shareholders have earned a 36% CAGR over the last five years
Silence Therapeutics plc ( LON:SLN ) shareholders might be concerned after seeing the share price drop 16% in the last...
- Motley Fool
Silence Therapeutics plc (SLN) Q2 2021 Earnings Call Transcript
Joining me today on the call are Mark Rothera, our president and CEO, who will provide an update on the business; Dr. Giles Campion, our head of R&D and chief medical officer, who will provide an update on our clinical programs; and Craig Tooman, our chief financial officer, who will review our financials before opening the call to your questions. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent annual report on file with the SEC.
© 2022 Yahoo. All rights reserved.
